000 | 03703nam a22005055i 4500 | ||
---|---|---|---|
001 | 978-1-59745-322-6 | ||
003 | DE-He213 | ||
005 | 20161121230737.0 | ||
007 | cr nn 008mamaa | ||
008 | 100301s2007 xxu| s |||| 0|eng d | ||
020 |
_a9781597453226 _9978-1-59745-322-6 |
||
024 | 7 |
_a10.1007/978-1-59745-322-6 _2doi |
|
050 | 4 | _aRB45 | |
072 | 7 |
_aMJF _2bicssc |
|
072 | 7 |
_aMED038000 _2bisacsh |
|
082 | 0 | 4 |
_a616.15 _223 |
245 | 1 | 0 |
_aAcute Myelogenous Leukemia _h[electronic resource] / _cedited by Judith E. Karp. |
264 | 1 |
_aTotowa, NJ : _bHumana Press, _c2007. |
|
300 |
_aXIV, 426 p. 55 illus., 14 illus. in color. _bonline resource. |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
347 |
_atext file _bPDF _2rda |
||
490 | 1 | _aContemporary Hematology | |
505 | 0 | _aOverview of AML -- Approaching the Treatment of AML from a Biological Perspective -- Molecular Foundations of AML Pathogenesis and Physiology -- Aberrant Transcription Factors in AML -- Myelodysplasia-Related AML -- Therapy-related AML -- The DNA Damage Response, DNA Repair, and AML -- Altered Apoptosis in AML -- Drug Resistance Transporters in AML -- Translating Biology into Clinical Application -- Impact of Cytogenetics on Clinical Outcome in AML -- APL: A Classic Tale of Bench to Bedside -- Molecular Therapeutics of AML: Selected Targeted Approaches -- Emerging Therapeutics for AML -- FLT3: A Prototype Receptor Tyrosine Kinase Target in AML -- Farnesyl Transferase Inhibitors in the Therapy of AML -- Modulating Gene Expression as a Therapeutic Approach in the Treatment of AML -- Differentiation Therapy in AML -- Stem Cell Transplantation for AML -- Tumor Vaccines in Leukemia -- Special Challenges -- Treatment, Outcomes, and Challenges of Newly Diagnosed AML in Children and Adolescents -- AML in Older Adults -- Dameshek Smiles: Molecular Clues to the Chronic Myeloproliferative Disorders Unmasked -- New Designs for Clinical Trials. | |
520 | _aAcute Myelogenous Leukemia is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML). The focus is on selected critical molecular determinants of AML pathogenesis and pathophysiology and the exploitation of these factors by diverse therapeutic agents and modalities. Bringing together new concepts and findings in the basic and clinical science of AML, the book emphasizes the molecular basis for new therapies that stand to have the greatest potential impact on the clinical face of these diseases. The text provides insights into selected novel strategies currently and prospectively being developed, including interruption of specific signal transduction pathways, modulation of gene expression, attempts to reinstate differentiation, and immunomodulation. There is an emphasis throughout on the bidirectional flow of knowledge between the clinical and laboratory arenas, and both basic and clinical scientists will benefit from this translational text. | ||
650 | 0 | _aMedicine. | |
650 | 0 | _aCancer research. | |
650 | 0 | _aInternal medicine. | |
650 | 0 | _aHematology. | |
650 | 0 | _aOncology. | |
650 | 1 | 4 | _aMedicine & Public Health. |
650 | 2 | 4 | _aHematology. |
650 | 2 | 4 | _aOncology. |
650 | 2 | 4 | _aCancer Research. |
650 | 2 | 4 | _aInternal Medicine. |
700 | 1 |
_aKarp, Judith E. _eeditor. |
|
710 | 2 | _aSpringerLink (Online service) | |
773 | 0 | _tSpringer eBooks | |
776 | 0 | 8 |
_iPrinted edition: _z9781588296214 |
830 | 0 | _aContemporary Hematology | |
856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-1-59745-322-6 |
912 | _aZDB-2-SME | ||
950 | _aMedicine (Springer-11650) | ||
999 |
_c503324 _d503324 |